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Abstract
Background. Depatuxizumab mafodotin (Depatux-M) is a tumor-specific antibody–drug conjugate consisting 
of an antibody (ABT-806) directed against activated epidermal growth factor receptor (EGFR) and the toxin 
monomethylauristatin-F. We investigated Depatux-M in combination with temozolomide or as a single agent in a 
randomized controlled phase II trial in recurrent EGFR amplified glioblastoma.
Methods. Eligible were patients with centrally confirmed EGFR amplified glioblastoma at first recurrence after 
chemo-irradiation with temozolomide. Patients were randomized to either Depatux-M 1.25 mg/kg every 2 weeks 
intravenously, or this treatment combined with temozolomide 150–200 mg/m2 day 1–5 every 4 weeks, or either 
lomustine or temozolomide. The primary endpoint of the study was overall survival.
Results. Two hundred sixty patients were randomized. In the primary efficacy analysis with 199 events (median fol-
low-up 15.0 mo), the hazard ratio (HR) for the combination arm compared with the control arm was 0.71 (95% CI = 0.50, 
1.02; P = 0.062). The efficacy of Depatux-M monotherapy was comparable to that of the control arm (HR = 1.04, 95% 
CI = 0.73, 1.48; P = 0.83). The most frequent toxicity in Depatux-M treated patients was a reversible corneal epitheliopathy, 
occurring as grades 3–4 adverse events in 25–30% of patients. In the long-term follow-up analysis with median follow-up 
of 28.7 months, the HR for the comparison of the combination arm versus the control arm was 0.66 (95% CI = 0.48, 0.93).
Conclusion. This trial suggests a possible role for the use of Depatux-M in combination with temozolomide in 
EGFR amplified recurrent glioblastoma, especially in patients relapsing well after the end of first-line adjuvant 
temozolomide treatment. (NCT02343406)
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Patients with glioblastoma still have a very limited prog-
nosis. Standard of care consists of surgery as feasible fol-
lowed by chemoradiotherapy with temozolomide (TMZ).1 
Once tumors progress after first-line treatment, treatment 
options are limited. Lomustine is often used for salvage 
therapy, which drug was used for comparison in several 
recent randomized studies on recurrent glioblastoma.2,3 
Rechallenge with TMZ is an option in selected patients, 
in particular those relapsing more than 2–3  months after 
the end of TMZ chemotherapy.4,5 Promoter methylation 
of O6-methylguanine-DNA methyltransferase (MGMT) is 
prognostic for treatment with both lomustine and TMZ in re-
current glioblastoma.2,4,6,7
Epidermal growth factor receptor (EGFR) signaling ab-
normalities have a prominent role in the pathogenesis 
of glioblastoma. In 45–50% of patients, the EGFR gene is 
amplified, usually accompanied by secondary mutations. 
The most common of these is the deletion of exons 2–7, 
known as EGFR variant (v)III, present in approximately 
half of all EGFR amplified glioblastomas. Trials of EGFR in-
hibitors and antibodies directed against EGFR in glioblas-
toma failed, however, to improve outcome.8–13 A different 
approach toward extracellular cancer cell targets consists 
of antibody–drug conjugates (ADCs) in which, after re-
ceptor binding and internalization, a potent cytotoxin is 
released inside the cell. Examples of this class of agents 
are trastuzumab emtansin and brentuximab vedotin.14,15 
Depatuxizumab mafodotin (Depatux-M, formerly known 
as ABT-414) is a newer generation ADC consisting of 
a veneered “humanized” recombinant immunoglob-
ulin G1κ antibody that has binding properties specific to 
a unique epitope of human EGFR, which is attached with 
non-cleavable maleimido-caproyl linkers to a potent anti-
microtubule agent, monomethylauristatin-F (MMAF). In 
a U87MG model expressing EGFRvIII, the activity of radi-
otherapy and TMZ was increased when Depatux-M was 
coadministered, whereas Depatux-M plus TMZ was more 
effective compared with Depatux-M with radiotherapy 
(data on file). Phase I studies and dose expansion cohorts 
in recurrent glioblastoma treated with Depatux-M alone 
or in combination with TMZ showed objective responses 
in 7–14% of patients, with 25–29% of patients remaining 
free from progression at 6  months.16,17 A  usually revers-
ible corneal epitheliopathy was the dose limiting toxicity, 
occurring as a grades 3–4 adverse event in 22–33% of pa-
tients. These studies also suggested EGFR amplification as 
the best biomarker to identify for activity of Depatux-M. 
Research on paired glioblastoma samples taken from 
first diagnosis and at the time of progression shows that 
in 80–90% of cases the EGFR amplification status is un-
changed at the time of progression, whereas expression of 
EGFRvIII often changes.18,19 We conducted a controlled ran-
domized trial on Depatux-M in EGFR amplified recurrent 
glioblastoma.
Materials and Methods
The INTELLANCE 2/European Organisation for Research 
and Treatment of Cancer (EORTC) 1410 study is a 
multicenter 3-arm comparative, randomized open label 
phase II trial in glioblastoma at first recurrence after chemo-
irradiation with TMZ, with overall survival (OS) as the pri-
mary endpoint, comparing the activity of (i) Depatux-M in 
combination with TMZ and of (ii) Depatux-M monotherapy 
with a control arm treated with either lomustine or TMZ. 
Eligible were patients 18 years or older with histologically 
confirmed glioblastoma, with centrally confirmed EGFR 
amplification, relapsing more than 3  months after the 
end of radiotherapy. Prior treatment with nitrosoureas, 
bevacizumab, or EGFR targeting agents was not allowed. 
Chemotherapy had to be discontinued at least 4 weeks 
prior to randomization. Surgery at the time of the recur-
rence was allowed, but required an MRI made within 48 
hours following surgery. Patients who were reoperated for 
the recurrence needed to have a bidimensionally measur-
able enhancing lesion with minimal square diameters of 
10 mm on MRI, with stable or decreasing dose of steroids 
for 7 days prior to the baseline MR scan. Eligibility required 
adequate hematological, renal, and hepatic function, and 
for women of childbearing potential a negative pregnancy 
test. Use of enzyme inducing anti-epileptic drugs was not 
allowed. Tumor material from surgery at diagnosis or at 
recurrence was required for central testing for EGFR am-
plification. Fluorescence in situ hybridization was used 
to detect locus-specific EGFR amplification as described 
elsewhere.20 To call a tumor EGFR amplified, the sample 
needed to show ≥15% tumor cells with an EGFR/chromo-
some enumeration probe 7 ratio of ≥2. The presence of 
an EGFRvIII mutation was determined by a custom triplex 
real-time reverse-transcription quantitative polymerase 
chain reaction (PCR) on RNA extracted from formalin-
fixed paraffin embedded tissue as described elsewhere.20 
MGMT promoter methylation status was determined using 
a methylation-specific PCR as described elsewhere.21
Importance of the Study
This is the first controlled study of Depatux-M, an anti-
body–drug conjugate targeting EGFR. The study evaluated 
Depatux-M alone and in combination with temozolomide 
in EGFR amplified glioblastoma at first recurrence. The 
results of the study suggest a role of Depatux-M in com-
bination with temozolomide, but ocular toxicity related 
to the attached toxin monomethylauristatin-F interfered 
with Depatux-M dose intensity and is likely to have af-
fected treatment outcome. New antibody–drug conju-
gates need to be developed aiming at EGFR, with more 
stable linker technology and better tolerance. Early 
in the development of such an agent, phase 0 studies 
should be conducted to evaluate intratumoral pharma-
cokinetics and pharmacodynamics.
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Treatment
Patients were 1:1:1 randomized to treatment with either 
Depatux-M 1.25 mg/kg intravenously over 30–40 minutes 
once every 2 weeks in combination with TMZ 150–200 mg/
m2 day 1–5 in 28 day cycles; monotherapy with Depatux-M 
at the same dose; or either lomustine or TMZ according to 
the timing of relapse. In the control arm, patients who re-
lapsed during TMZ treatment or within the first 16 weeks 
after the first day of the last TMZ cycle received lomustine 
110 mg/m2 (maximum dose 200 mg) on day 1 of 42-day 
treatment periods, whereas patients relapsing after-
ward were treated with TMZ 150–200 mg/m2 on day 1–5 
in 28-day cycles. Shortly after the start of the trial, the 
Depatux-M start dose was decreased from 1.25 mg/kg to 
1.0 mg/kg because of ocular toxicity reported in the on-
going phase I trial. Patients treated with Depatux-M were 
given for 7 days steroid eye-drops starting 48 hours be-
fore administration as prophylactic treatment of ocular 
side effects.
TMZ could be dose reduced to 150 mg/m2 (from 200 mg/
m2) or to 100 mg/m2 in case of toxicities. Lomustine was 
given in tablets of 40 mg, with the dosage rounded to the 
nearest 40 mg. In case of toxicities, the dose was reduced 
to 90 mg/m2 or to 70 mg/m2. Depatux-M dose was not dose 
reduced in case of grades 1 and 2 toxicities. In the event of 
a first grade 3 toxicity, after recovery to grade 1 or base-
line treatment could be restarted at 1.0 mg/kg or reduced 
to 0.75 mg/kg of Depatux-M. In case of repeated grade 3 
toxicity, Depatux-M could continue at 0.75mg/kg or could 
be dose reduced to 0.5 mg/kg.
Follow-up Schedule
The baseline evaluation included a standardized MRI 
protocol,22 clinical and neurological evaluation, health-
related quality of life (HRQoL) evaluation, ECG, complete 
blood count, blood chemistry, and urine-analysis, to be 
repeated every 8 weeks. Patients were evaluated for vital 
signs, adverse events, and hematology exam at the start 
of each treatment cycle. Toxicities were collected using 
the Common Terminology Criteria for Adverse Events 4.0 
(https://ctep.cancer.gov/protocoldevelopment/electronic_
applications/ctc.htm#ctc_40).
HRQoL was assessed with the EORTC Quality of Life 
Core Questionnaire (QLQ-C30) version 3 and the EORTC 
Brain Cancer module (QLQ-BN20).23
Potentially eligible patients were first registered by the 
treating institutions for assessment of EGFR amplification 
and EGFRvIII status in the EORTC web-based registration 
and randomization system (http://www.eortc.org/inves-
tigators/). Upon confirmation of eligibility, patients were 
randomized to one of the treatment arms. Patients were as-
signed a stratum by a minimization procedure based on the 
variance method with semi-random assignment, to reduce 
treatment allocation predictability, and 15% of patients 
were completely randomly assigned.24,25 Stratification fac-
tors were World Health Organization performance status, 
time of relapse (<16 or ≥16 weeks after the first day of the 
last TMZ cycle), and region of the world (North America vs 
Europe and Australia vs Asia/other regions).
Statistical Design and Analysis
The primary endpoint of the study was OS in the intent-
to-treat population. Secondary endpoints were OS in the 
subgroup with EGFRvIII mutation, progression-free sur-
vival (PFS; assessed by independent review), and objective 
response rate (ORR) per independent review (Response 
Assessment in Neuro-Oncology criteria).26 Assuming 
a median OS of 7 months in the control arm, based on a 
one-sided log-rank test, at an overall significance level 
of 2.5% and a power of 91.7% (accounting for the global 
testing strategy), a total of 170 survival events (and 118 
events per comparison, ie, monotherapy Depatux-M vs 
control and combination Depatux-M + TMZ vs control) 
would be needed to detect an increase of median OS to 
12.9  months in the Depatux-M treatment arms, corre-
sponding to a hazard ratio (HR) of 0.54.
A multiple testing strategy was implemented to con-
trol the family-wise type I  error (alpha) for compari-
sons (i) of arm 1 (Depatux-M+ TMZ) versus arm 3 (TMZ/
lomustine) and (ii) of arm 2 (Depatux-M monotherapy) 
versus arm 3 with respect to OS and the predefined sec-
ondary efficacy endpoints, namely PFS, ORR, and OS for 
patients with EGFR vIII mutation. They were tested in the 
following order: H1, H2, H1a, H2a, H1b, H2b, H1c, H2c 
at a 1-sided 2.5% level of significance (Supplementary 
Figure 4). Each hypothesis was tested in order specified 
above if H1 and all preceding hypotheses showed statis-
tically significant results at the 1-sided 2.5% level of sig-
nificance. The testing sequence was stopped at the first 
nonsignificant test.
OS was measured from the date of randomization until 
the date of death; patients alive at the end of the study 
were right-censored on the date they were last known to 
be alive. PFS was calculated from the date of randomi-
zation to documented disease progression or death, 
whichever occurred first; patients alive and free from 
progression at the time of analysis were right-censored 
at their last tumor assessment date. For OS and PFS, log-
rank tests stratified by the randomization stratification 
factors were used for primary inference, and Cox models 
adjusting for the same factors as covariates were used for 
estimating the HR of the 2 treatment arms over the con-
trol arm. To assess the predictive value of these factors 
for OS and PFS, the score interaction test was computed 
by fitting a Cox regression model including treatment, 
factor, and interaction term (Treatment × Factor). In 
prespecified subgroup analysis, efficacy endpoints were 
assessed in the subgroups based on the timing of relapse 
(<16 wk or ≥16 wk after the first day of the last TMZ cycle) 
and MGMT promoter methylation status (methylated or 
unmethylated).
The protocol was approved by the ethics committees 
and competent authorities of all participating centers and 
countries. All patients gave written informed consent for 
trial participation. AbbVie sponsored the study. The study 
protocol was developed by the principal investigator 
(M.v.d.B.) and the EORTC Headquarters staff (T.G., V.G.) 
in collaboration with the study sponsor. Central testing of 
tumor samples for EGFR status was done at Histogenex 
for Europe; Mosaic for North and South America; and 
Peter Mac for Australia and Asia. All clinical data were 
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collected and reviewed by EORTC staff and the principal 
investigator. The clinical database was maintained and 
controlled by EORTC. The central imaging review was con-
ducted by an independent neuroradiologist (M.S.). The 
MR images were centrally collected at Parexel; the cen-
tral imaging review was conducted by an independent 
neuroradiologist (M.S.). The principal investigator had full 
access to all data and the final responsibility to submit for 
publication. The study was registered at EudraCT# 2014-
004438-24 and ClinicalTrials.gov NCT02343406. The full 
study protocol can be reviewed at https://www.eortc.be/
services/doc/protocols/1410.pdf.
Results
Registered into the study were 1135 patients between 
February 16, 2015 and July 1, 2016, and 260 patients were 
randomized between March 10, 2015 and July 22, 2016. 
The most important reason for non-randomization was 
absence of EGFR amplification (55.4%); for 20% of tested 
patients the trial was closed prior to tumor progression 
(Fig. 1). At review, 20 patients were considered not eligible 
(most important reasons: no MRI/target lesion at base-
line available [n =  9], poor performance status [n =  5]). 
Eighty-eight patients were randomized to the combina-
tion Depatux-M + TMZ arm, 86 patients to the Depatux-M 
monotherapy arm, and 86 patients to the control arm 
(lomustine n = 61, TMZ n = 25). Table 1 summarizes the pa-
tient baseline characteristics; no major imbalances were 
observed. Eleven patients did not start the assigned treat-
ment (Depatux-M monotherapy arm = 2; control arm = 9; 
lomustine  =  5; TMZ  =  4). Median duration of Depatux-M 
treatment was 16 weeks in the combination arm and 9.0 
weeks in the monotherapy arm. Depatux-M dose intensity 
was above 90% in 33% of patients in the combination arm 
and in 50% in the monotherapy arm. The median duration 
of TMZ treatment was 9.0 weeks with a relative dose in-
tensity above 90% in 66.7% of patients—for lomustine this 
was 12.0 weeks and 41.1%. Table 2 summarizes adverse 
events occurring in more than 10% of patients or of spe-
cial interest. The most frequent grades 3–4 related toxicity 
in Depatux-M treated patients was corneal epitheliopathy 
(combination arm  =  32.9% of patients, monotherapy 
arm = 23.8% of patients). In the control arm the most fre-
quent grades 3–4 toxicities were hematological, occurring 
in 43% of patients.
  
Number of patients registered: 1135
Not EGFR amplified: 485
No EGFR amplification result: 28
Accrual closed prior to PD: 174
Patient refusal: 54
Not meeting inclusion criteria: 27
Other: 107
Number of patients randomized: 260
Depatux M monotherapy
Randomized: 86
Never started treatment: 2
Not eligible: 2
Control arm TMZ or lomustine
Randomized: 86
Lomustine: 61
Temozolomide: 25
Never started treatment: 9
Lomustine: 4
Temozolomide: 5
Not eligible: 9
Depatux M with temozolomide
Randomized: 88
Not eligible: 3
Treatment discontinued for:
Toxicity: 5
Progression or death: 66
Withdrawal: 4
Other: 1
Treatment ongoing: 12
Treatment discontinued for:
Toxicity: 7
Progression or death: 71
Withdrawal: 3
Other: 2
Treatment ongoing: 1
Treatment discontinued for:
Toxicity: 9
Progression or death: 58
Withdrawal: 6
Other: 2
Normal completion: 1
Treatment ongoing: 1
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) flow diagram of EORTC study 1410, at the time of primary analysis.
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Efficacy
The primary analysis of the study was performed in 
September 2017 when 199 subjects had died and 133 sur-
vival events had been observed for the primary compar-
ison between the combination Depatux-M with TMZ and 
the control arm. With a median follow-up of 14.4 months, 
238 patients had PFS events and 4 patients were lost to fol-
low-up (2 in the combination arm and 2 in the control arm). 
In the primary comparison of the combination arm versus 
the control arm, the null OS hypothesis was not rejected 
(HR of 0.71, 95% CI [0.50, 1.02]; log rank P = 0.06). The mul-
tiple testing strategy was stopped at this first nonsignificant 
result and further efficacy analyses were performed on 
an exploratory basis at 5% two-sided significance levels. 
For the second comparison, monotherapy arm versus the 
control arm, the null OS hypothesis was also not rejected 
(HR 1.04, 95% CI [0.73, 1.48]; log rank P = 0.83).
A long-term analysis (LTA) was performed in October 
2018, more than 24  months after the last patient was 
randomized. At this analysis, median follow-up was 
28.7  months, all patients had discontinued treatment, 
251 patients (96.5%) had progressed or died, 237 patients 
(91.2%) had died. From an additional 2 patients, follow-up 
data were missing. At the LTA, for the primary compar-
ison of the combination arm versus the control arm, an 
HR of 0.66, 95% CI [0.47, 0.93], log rank P  =  0.017 were 
observed. For the second comparison (monotherapy 
Depatux-M vs the control arm), HR of 0.96 [0.69, 1.33], 
log rank P  =  0.80 were observed. Fig. 2 shows the OS 
Kaplan–Meier curves of both comparisons, with ongoing 
separation of the survival curves in the first comparison. 
  
Table 1. Patient characteristics at randomization in the 3 treatment groups, n (%) 
Patient Characteristic TMZ + ABT-414 
(n = 88)
ABT-414 
(n = 86) 
TMZ or Lomustine 
(n = 86) 
All 
(N = 260) 
Sex
 Male 59 (67.0) 50 (58.1) 58 (67.4) 167 (64.2)
 Female 29 (33.0) 36 (41.9) 28 (32.6) 93 (35.8)
Age     
 Median 59.2 58.3 58.8 58.7 
 Range 40.1–75.4 36.3–79.3 34.9–82.3 34.9–82.3 
 <40 y 0 (0.0) 3 (3.5) 5 (5.8) 8 (3.1) 
 ≥40–<60 y 46 (52.3) 45 (52.3) 39 (45.3) 130 (50.0) 
 ≥60 y 42 (47.7) 38 (44.2) 42 (48.8) 122 (46.9) 
World Health Organization performance status     
 0 28 (31.8) 30 (34.9) 30 (34.9) 88 (33.8) 
 1 45 (51.1) 36 (41.9) 42 (48.8) 123 (47.3) 
 2 15 (17.0) 20 (23.3) 14 (16.3) 49 (18.8)
Time of relapse     
 <16 weeks after the first day of the last TMZ cycle 60 (68.2) 59 (68.6) 60 (69.8) 179 (68.8)
 ≥16 weeks after the first day of the last TMZ cycle 28 (31.8) 27 (31.4) 26 (30.2) 81 (31.2)
MGMT status     
 Unmethylated 45 (51.1) 44 (51.2) 44 (51.2) 133 (51.2)
 Methylated 43 (48.9) 41 (47.7) 42 (48.8) 126 (48.5) 
 Missing 0 (0.0) 1 (1.2) 0 (0.0) 1 (0.4)
EGFRvIII mutation     
 Absent 47 (53.4) 45 (52.3) 36 (41.9) 128 (49.2)
 Present 39 (44.3) 36 (41.9) 47 (54.7) 122 (46.9)
 Missing 2 (2.3) 5 (5.8) 3 (3.5) 10 (3.8) 
Time since diagnosis of recurrence/progression (weeks)     
 Mean (SD) 6.03 (4.30) 5.81 (3.31) 6.23 (4.56) 6.02 (4.08) 
Surgery for recurrence     
 No 67 (76.1) 64 (74.4) 63 (73.3) 194 (74.6)
 Yes 21 (23.9) 22 (25.6) 23 (26.7) 66 (25.4)
Use of steroids     
 No 49 (55.7) 45 (52.3) 41 (47.7) 135 (51.9) 
 Yes 39 (44.3) 41 (47.7) 45 (52.3) 125 (48.1)
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Table 3 presents the HR for OS in the first and the second 
comparison in predefined subgroups. Table 4 lists me-
dian PFS, median OS, 12 and 24 months OS in the LTA. 
(Supplementary Table 1A–C  lists the comparisons in the 
predefined subgroup for OS at the time of primary anal-
ysis, and OS and PFS by independent review at the time 
of LTA. Supplementary Table 2 lists PFS and OS param-
eters in the control group related to MGMT promoter 
methylation status. Supplementary Table 3 lists the me-
dian OS and 24 months OS in the predefined subgroups 
and Supplementary Figures 1–3 present OS and PFS in 
predefined subgroups.) Interaction tests for MGMT pro-
moter status, EGFRvIII status, and time of relapse (less 
or more than 16 weeks after the end of first-line TMZ) re-
mained negative. For the second comparison, Depatux-M 
monotherapy versus control, a stratification factor ad-
justed HR of 0.96 (0.69, 1.33; P = 0.80) was observed—for 
MGMT promoter unmethylated (n =  88), an HR of 1.22 
(0.75, 1.97, P = 0.43); for MGMT promoter methylated (n 
=  83), an HR of 0.81 (0.49, 1.33, P  =  0.40). Objective re-
sponses were infrequent; Supplementary Table 4 lists the 
responses by the central reviewer. No major differences 
were observed with respect to treatment at progression 
between the treatment arms (Supplementary Table 5). 
Detailed analyses of HRQoL findings and of neurological 
deterioration-free survival will be reported elsewhere.
Discussion
This is the first controlled trial on an antibody–drug con-
jugate in glioblastoma, specifically targeting EGFR amp-
lified glioblastoma. In the primary analysis with 199 
events, a trend was observed in favor of Depatux-M in 
combination with TMZ compared with the control arm. In 
the long-term follow-up analysis, the OS difference be-
tween these two arms became statistically significant 
(P  =  0.017). In that analysis, the 2-year survival in the 
combination arm was 19.8% (95% CI: 12.2, 28.8), in the 
control arm 5.2% (95% CI: 1.7, 11.7), and in the Depatux-M 
monotherapy arm 10% (95% CI: 4.8, 17.6). MGMT status 
was not associated with the observed HR, neither in 
the combination arm nor in the monotherapy arm. 
Interestingly, 2-year survival in the group of patients 
who relapsed more than 16 weeks after the end of TMZ 
  
Table 2. Treatment emergent adverse events occurring in more than 10% of patients or of special interest per treatment arm 
Depatux-M with 
Temozolomide 
N = 88
Depatux-M 
N = 84
Lomustine or Temozolomide 
N = 77 (56*/21)
Grade 1–2 3 4 5 1–2 3 4 5 1–2 3 4 5
Gastrointestinal 
 Nausea 
 Diarrhea
47 
21 
8
   25 
8 
6
3 
1
  25 
12 
4
2  1
Eye disorders 44 28 1  40 19 1  3    
Infections 25 4  1 18 4   8 3  1
Investigations 
 ALAT increase 
 Bilirubin 
 Glucose
49 
8 
3
1 
3
  
33 
6 
3
1
  
19*/6 
5 
2
2*/0
  
Fatigue 26 7   24 4   15 1   
Hematology 
Hemoglobin 
WBC 
Neutrophils 
Lymphocytes 
Platelets 
Any
27 
25 
14 
35 
54 
49
1 
2 
2 
26 
7 
28
2 
1 
3
 
24 
11 
5 
29
1 
10 
1 
11
  
31*/8 
23*/6 
14*/2 
25*/9 
36*/9 
14*/9
8*/0 
8*/1 
15*/5 
11*/3 
15*/8
3*/0 
2*/0 
3*/1 
3*/0 
9*/1
 
Febrile neutropenia          1   
Musculoskeletal 25 2   13 3   12 4   
Nervous system 36 17 4  37 19 1 1 28 13  2
Respiratory 
 Pulmonary embolism
15 
0
5 
2
1 
1
3 
1
6    9 
0
3 
3
  
Venous thrombosis 1    1    1 2   
Rash 7    2    3    
Nervous system 35 18 4  37 20 1 1 32 12  2
ALAT = alanine aminotransferase; WBC = white blood cell.
In the control arm, for ALAT and hematology adverse events, rates were higher in the lomustine treated patients compared with temozolomide 
treated patients. *Lomustine treated patients.
One patient in the Depatux-M monotherapy arm died from an intracranial hemorrhage that was considered related.
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Fig. 2 (A) Overall survival (Kaplan–Meier) curve for the comparison between Depatux-M with temozolomide versus the control arm (lomustine or 
temozolomide) at the time of long-term follow-up. (B) Overall survival (Kaplan–Meier) curve for the comparison between Depatux-M monotherapy 
versus the control arm (lomustine or TMZ) at the time of long-term follow-up.
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treatment was 28.6% (95% CI: 13.5, 45.6) for the combi-
nation arm, 11.1% (95% CI: 2.8, 25.9) for the Depatux-M 
monotherapy arm, and 3.9% (95% CI: 0.3, 16.4) for the 
control arm. Combined, these data suggested clinical 
benefit of the combination Depatux-M + TMZ in recur-
rent EGFR amplified glioblastoma, especially in patients 
relapsing more than 16 weeks after the start of the last 
TMZ cycle. However, no evidence of efficacy in the 
monotherapy arm was observed, which is in particular 
remarkable for the subgroup with the MGMT promoter 
unmethylated tumors. In that group of patients, no clin-
ical relevant activity of lomustine or TMZ is anticipated. 
In a companion trial, the INTELLANCE I phase III study, 
the addition of Depatux-M to standard chemo-irradiation 
with TMZ is investigated in newly diagnosed EGFR ampli-
fied glioblastoma patients (NCT02573324). After a recent 
interim analysis, this trial was discontinued for futility. 
The negative outcome of this trial questions the findings 
in the combination arm of the present phase II study in 
recurrent glioblastoma, but the possibility remains that a 
more favorable subset of recurrent glioblastoma patients 
does indeed benefit from the combination Depatux-M 
+ TMZ.
The toxicity profile of Depatux-M was similar to 
the observed toxicities in the phase I  study: a corneal 
epitheliopathy grade 3 or 4 occurring in 25–30% of pa-
tients. Although in only a few patients this resulted in 
treatment discontinuation, the required dose reductions 
may have impacted the outcome of Depatux-M treat-
ment. This toxicity is due to off-target effects of the toxin, 
which has also been observed in other ADCs that contain 
MMAF.27 Limitations of this study include the relatively 
limited sample size per arm, the number of patients in 
the control arm who did not start the allocated treatment, 
and the absence of EGFR amplification assessment at first 
progression.
To conclude, this trial suggests a role for the use of 
Depatux-M in combination with TMZ in EGFR amplified re-
current glioblastoma, but its findings are not supported by 
the companion phase III study in newly diagnosed glioblas-
toma. The efficacy in glioblastoma of other ADCs targeting 
the EGFR but with a better safety profile should be explored.
For list of participating sites and accrual, see 
Supplementary Table 6.
Supplementary Material
Supplementary data are available at Neuro-Oncology 
online.
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Table 4. Progression-free survival, median OS, and survival at 12 and 24 months (95% CI) at the time of long-term follow-up analysis (237 events 
observed)
n Median PFS Median OS 12 mo OS 24 mo OS
Depatux-M + TMZ 88 2.7 (2.0, 3.8) 9.6 (7.4, 11.8) 39.7 (29.4, 49.7) 19.8 (12.2, 28.8)
Depatux-M 86 1.9 (1.9, 2.2) 7.9 (6.1, 8.7) 26.7 (17.9, 36.4) 10.0 (4.8, 17.6)
Lomustine or TMZ 86 1.9 (1.8, 2.0) 8.2 (5.9, 9.5) 28.2 (19.1, 37.9) 5.2 (1.7, 11.7)
  
  
Table 3. Hazard ratios [95% CIs] and P-values for OS at long-term follow-up in comparison to the control arm in the prespecified subgroup 
analyses
Depatux-M + Temozolomide Depatux-M Monotherapy
Relapse after TMZ 
≤16 weeks 
>16 weeks
 
0.77 [0.51, 1.14], P = 0.19 
0.46 [0.25, 0.88], P = 0.02
 
1.05 [0.72, 1.56], P = 0.79 
0.76 [0.41, 1.40], P = 0.37
MGMT promoter 
Methylated 
Unmethylated
 
0.68 [0.39, 1.16], P = 0.16 
0.63 [0.39, 1.03], P = 0.06
 
0.81 [0.49, 1.33], P = 0.40 
1.21 [0.75, 1.97], P = 0.43
EGFRvIII mutation 
Present 
Not present
 
0.70 [0.43, 1.13], P = 0.14 
0.66 [0.39, 1.13], P = 0.13
 
0.93 [0.57, 1.52], P = 0.77 
1.05 [0.64, 1.73], P = 0.84
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